Breaking News

Galena, Dr. Reddy's Enter Strategic NeuVax Pact

By Kristin Brooks | January 14, 2014

To expand development of breast cancer drug

Galena Biopharma and Dr. Reddy's Laboratories Ltd. have entered a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer. Based on a successful Phase II trial, which achieved its primary endpoint of disease-free survival, the FDA granted NeuVax a Special Protocol Assessment (SPA) for a Phase III study.
 
"This partnership with Dr. Reddy's is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy," said Mark J. Ahn, Ph.D., president and chief executive officer of Galena Biopharma. "The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population, if approved."
 
G V Prasad, chairman and chief executive officer, Dr. Reddy's, said, "The partnership accelerates our strong commitment to innovation and efforts to bring newer options for cancer patients. We are delighted with our partnership with Galena Biopharma and we believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important